Anyone who looks hard enough for signs of life in what has been biotech's worst public market since 2002 will likely find something. But now the something they find might be real.
It was hardly hard-core biotech, but in early August revenue-generating specialty pharma group Cumberland Pharmaceuticals Inc. raised $85 million in an IPO. [See Deal] Later that same week saw the debut of PE-backed health care IT firm Emdeon Inc. (See "Health Care IPOs: Is That a Breeze?" The IN VIVO Blog, August 12, 2009 [A#8491280417090031339].) And then in late August, some international action stirred the pot further. The more biotech-like D-Pharm Ltd
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?